Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ELI LILLY AND COMPANY

(LLY)
  Report
Delayed Nyse  -  04:03 2022-10-03 pm EDT
321.55 USD   -0.56%
09/29Oncology Institute Enrolls First Two Patients in US in Late-Stage Cancer Treatment Trial
MT
09/28Biogen shares soar on landmark Alzheimer's data
RE
09/28Eli Lilly Up Over 7%, on Track for Record High Close -- Data Talk
DJ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
All news about ELI LILLY AND COMPANY
09/29Oncology Institute Enrolls First Two Patients in US in Late-Stage Cancer Treatment Tria..
MT
09/28Biogen shares soar on landmark Alzheimer's data
RE
09/28Eli Lilly Up Over 7%, on Track for Record High Close -- Data Talk
DJ
09/28MarketScreener's World Press Review : September 28, ..
MS
09/28Thermo Fisher Scientific's Cancer Screening Technology Gets FDA Approval
MT
09/27Eisai says Alzheimer's drug succeeds in slowing cognitive decline
RE
09/27Eli Lilly Faces US Lawsuit Over Age Discrimination In Sales Jobs
MT
09/26Eli Lilly sued for age discrimination by U.S. agency EEOC
RE
09/23Medical device makers see little impact from Fiona on Puerto Rico operations
RE
09/22US Stocks End Lower Thursday Despite Healthcare Gains
MT
09/22US Stocks End Lower Thursday Despite Surge in Healthcare Shares
MT
09/22Sector Update: Health Care Stocks Gain Thursday Afternoon
MT
09/22Sector Update: Health Care Stocks Rising in Defensive Thursday Trading
MT
09/22Sector Update: Health Care
MT
09/22Eli Lilly Gains After FDA Approves Retevmo for Adult Patients With Solid Tumors, UBS U..
MT
09/22UBS Upgrades Eli Lilly and Company to Buy From Neutral, Adjusts Price Target to $363 Fr..
MT
09/22Eli Lilly Says FDA Approves Retevmo for Adult Patients with Advanced or Metastatic Soli..
MT
09/21FDA Approves Lilly's Retevmo« (selpercatinib), the First and Only RET Inhibitor for Adu..
PR
09/21FDA Approves Eli Lilly and Company's Retevmo (selpercatinib), the First and Only RET In..
CI
09/20Veru Announces FDA has Updated the Meeting Date for the Advisory Committee Meeting to R..
AQ
09/14Capstan Therapeutics, Inc. announced that it has received $101.999962 million in fundin..
CI
09/13Transcript : Eli Lilly and Company Presents at Morgan Stanley 20th Annual Glo..
CI
09/08Almirall, Lilly Report 'Robust and Durable' Phase 3 Results in Atopic Dermatitis Treatm..
MT
09/08Lebrikizumab Dosed Every Four Weeks Maintained Durable Skin Clearance in Lilly's Phase ..
PR
09/08Lebrikizumab Dosed Every Four Weeks Maintained Durable Skin Clearance in Lilly's Phase ..
CI
09/08Photys Therapeutics, Inc. announced that it has received $75.000001 million in funding ..
CI
09/07Lilly Announces Details of Presentations at ESMO Congress 2022
PR
09/07Transcript : Eli Lilly and Company Presents at Citi's 17th Annual BioPharma C..
CI
09/07Morgan Stanley Adjusts Eli Lilly's Price Target to $412 From $395, Reiterates Overweigh..
MT
09/06Insider Sell: Eli Lilly
MT
09/06BMO Capital Adjusts Eli Lilly's Price Target to $396 From $369, Maintains Outperform Ra..
MT
09/02Eli Lilly And : 2022 CDP Climate Change Report
PU
09/02Eli Lilly And : 2022 CDP Water Security Report
PU
08/31Lilly to Participate in Morgan Stanley 20th Annual Global Healthcare Conference
PR
08/27AstraZeneca's Farxiga cuts death risk in heart failure patients -study
RE
08/25Lilly to Participate in Citi's 17th Annual BioPharma Conference
PR
08/25Citigroup Adjusts Eli Lilly's Price Target to $370 From $285, Reiterates Buy Rating
MT
08/25Aclaris Therapeutics Signs Non-Exclusive Patent License Agreement With Eli Lilly for Al..
MT
08/17Direct Relief Delivers Seven-Week Supply of Long-Acting Insulin to Ukraine, Donated by ..
AQ
08/16Insider Buy: Eli Lilly
MT
08/12ELI LILLY AND COMPANY : Ex-dividend day for
FA
08/11First Patient Dosed in ALX Oncology's Mid-Stage Trial of Colorectal Cancer Combination ..
MT
08/11Lilly Announces Leadership Transition in Human Resources and New Chief Commercial Offic..
PR
08/11Eli Lilly and Company Announces Executive Changes
CI
08/10Sermonix to Host Virtual Clinical Update on its ELAINE Phase 2 Clinical Programs
AQ
08/08Lilly's Taltz« (ixekizumab) Now Available in New, Citrate-Free Formulation to Reduce In..
PR
08/08Eli Lilly and Company Announces the Availability of a New, Citrate-Free Formulation of ..
CI
08/08Eli Lilly May Divert Employment Outside Indiana After US State OKs Abortion Bill
MT
08/06Biden team, Eli Lilly condemn new Indiana abortion ban
AQ
08/05Goldman Sachs Adjusts Price Target for Eli Lilly and Company to $273 From $277, Maintai..
MT
08/05Eli Lilly Stock Outlook Unchanged After Q2 Update But 'Mixed Elements' to Consider, Gol..
MT
08/05PUMP / DUMP #40 : This week's gainers and losers
MS
08/05Another case of good news is bad news
MS
08/04Cantor Fitzgerald Raises Price Target for Eli Lilly and Company to $360 From $335, Main..
MT
08/04ELI LILLY & CO Management's Discussion and Analysis of Results of Operations and Finan..
AQ
08/04Tranche Update on Eli Lilly and Company's Equity Buyback Plan announced on May 3, 2021.
CI
08/04Global markets live: Bayer, Merck, eBay, MetLife, Eli Lilly...
MS
08/04Transcript : Eli Lilly and Company, Q2 2022 Earnings Call, Aug 04, 2022
CI
08/04Eli Lilly Lowers 2022 Profit Outlook on Foreign Exchange Headwinds as Second-Quarter Re..
MT
08/04Lilly Updates Conference Call Start Time for Second-Quarter 2022 Financial Results
PR
08/04Sector Update: Health Care Stocks Mixed Pre-Bell Thursday
MT
08/04Still seeing the glass half full
MS
08/04Sector Update: Health Care
MT
08/04MarketScreener's World Press Review : August 4, 2022
MS
08/04Eli Lilly And : Q2 2022 Financial Workbook
PU
08/04Eli Lilly And : Lilly Reports Second-Quarter Financial Results, Highlights Momentum of New..
PU
08/04Eli Lilly Trims FY22 EPS Guidance Amid Weaker Q2 Results
MT
08/04Eli Lilly and Company's Q2 Adjusted Earnings, Revenue Fall
MT
08/04Eli Lilly And : Q2 2022 Lilly Press Release
PU
08/04Lilly : Q2 Earnings Snapshot
AQ
08/04Eli Lilly quarterly profit falls 31% on diabetes drug weakness
RE
08/04GUIDANCE: (LLY) ELI LILLY AND COMPANY Expects Fiscal Year 2022 EPS Range $7.90 ..
MT
08/04Lilly Reports Second-Quarter Financial Results, Highlights Momentum of New Medicines an..
PR
08/04Earnings Flash (LLY) ELI LILLY AND COMPANY Posts Q2 Revenue $6.49B
MT
08/04Earnings Flash (LLY) ELI LILLY AND COMPANY Reports Q2 EPS $1.25
MT
1  2  3  4  5  6  7  8  9  10Next
Upcoming event on ELI LILLY AND COMPANY